BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Thyroid cancer clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for thyroid cancer: 47 (34 sponsors; 6 newly posted in the last 180 days, 2 stopped in the last 180 days; 2 new-entrant sponsors). Momentum score 3.2, rank 90 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 1, Phase 1 14, Phase 2 12, Phase 3 5, Phase 4 5, N/A 10.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Exelixis EXEL | 4 | P3 2, P4 1, P1 1 | 1 | 0 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | P4 1, NA 1, P3 1 | 0 | 1 |
| Novartis Pharmaceuticals NVS | 3 | NA 1, P3 1, P1 1 | 1 | 1 |
| Loxo Oncology, Inc. | 1 | P3 1 | 0 | 0 |
| Eli Lilly and Company LLY | 5 | P2 3, P1 1, P4 1 | 1 | 0 |
| Novo Nordisk A/S NVO | 2 | NA 2 | 1 | 1 |
| Pfizer PFE | 2 | P1 2 | 0 | 0 |
| AccSalus Biosciences, Inc. | 1 | P1 1 | 0 | 0 |
| Adela, Inc | 1 | NA 1 | 0 | 1 |
| AffyImmune Therapeutics, Inc. | 1 | P1 1 | 0 | 0 |
| Alpha Fusion Inc. | 1 | P1 1 | 0 | 0 |
| Apollomics Inc. APLM | 1 | P2 1 | 0 | 0 |
| AstraZeneca AZN | 1 | NA 1 | 0 | 0 |
| Bayer | 1 | NA 1 | 0 | 0 |
| Beijing Scitech-Mq Pharmaceuticals Limited | 1 | P2 1 | 0 | 0 |
| Degron Therapeutics Co. | 1 | P1 1 | 0 | 0 |
| Erasca, Inc. ERAS | 1 | P1 1 | 0 | 0 |
| FindCure Biosciences (ZhongShan) Co., Ltd. | 1 | EARLY_P1 1 | 0 | 1 |
| Fore Biotherapeutics | 1 | P2 1 | 0 | 0 |
| Hoffmann-La Roche | 1 | P2 1 | 0 | 0 |
| Jazz Pharmaceuticals JAZZ | 1 | P1 1 | 0 | 0 |
| Merck Sharp & Dohme LLC MRK | 1 | P2 1 | 0 | 1 |
| ModeX Therapeutics, An OPKO Health Company | 1 | P2 1 | 0 | 0 |
| Pierre Fabre Medicament | 1 | P1 1 | 0 | 0 |
| Power Life Sciences Inc. | 1 | NA 1 | 0 | 0 |
Recently stopped trials
- NCT05451602 Sunshine Lake Pharma Co., Ltd. - terminated: Sponsor strategic decision; the study will not continue. HEC169096 in Participants With Advanced Solid Tumors
- NCT07181720 Chongqing Precision Biotech Co., Ltd - suspended: Sponsor stopped the study. CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2027-01 est. | P3 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06860971 A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma | Thyroid Cancer | recruiting | 144 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-29 | P2 | Hoffmann-La Roche | NCT02568267 Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusio | Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, | completed | 534 |
| 2026-06-02 | P1/P2 | Sensei Biotherapeutics, Inc. | NCT05864144 A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | Solid Tumor, Adult; Advanced Solid Tumor; Head and Neck Cancer; Breast Cancer; Colon Cancer; Pancrea | completed | 98 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "thyroid cancer"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.